Literatur
-
1
Abizaid A, Costa M A, Centemero M. et al .
Clinical and economic impact of diabetes
mellitus on percutaneous and surgical treatment of multivessel coronary
disease patients: insights from the Arterial Revascularization Therapy
Study (ARTS) trial.
Circulation.
2001;
104
533-538
-
2
Abizaid A, Kornowski R, Mintz G S. et al .
The
influence of diabetes mellitus on acute and late clinical outcomes
following coronary stent implantation.
J Am Coll Cardiol.
1998;
32
584-589
-
3
Aronson D, Bloomgarden Z, Rayfield E J.
Potential
mechanisms promoting restenosis in diabetic patients.
J
Am Coll Cardiol.
1996;
27
528-535
-
4
BARI Investigators .
Influence
of diabetes on 5-year mortality and morbidity in a randomized trial
comparing CABG and PTCA in patients with multivessel disease: the
Bypass Angioplasty Revascularization Investigation (BARI).
Circulation.
1997;
96
1761-1769
-
5
BARI Investigators .
Seven-year
outcome in the Bypass Angioplasty Revascularization Investigation
(BARI) by treatment and diabetic status.
J Am Coll Cardiol.
2000;
35
1122-1129
-
6
Batchelor W B, Anstrom K J, Muhlbaier L H. et al .
Contemporary outcome trends in the elderly
undergoing percutaneous coronary interventions: results in 7,472
octogenarians. National Cardiovascular Network Collaboration.
J
Am Coll Cardiol.
2000;
36
723-730
-
7
Bell D S.
Diabetes
mellitus and coronary artery disease.
Coron Artery Dis.
1996;
7
715-722
-
8
Bhatt D L, Marso S P, Lincoff A M, Wolski K E, Ellis S G, Topol E J.
Abciximab reduces
mortality in diabetics following percutaneous coronary intervention.
J
Am Coll Cardiol.
2000;
35
922-928
-
9
Blindt R, Bosserhoff A K, Zeiffer U, Krott N, Hanrath P, vom Dahl J.
Abciximab
inhibits the migration and invasion potential of human coronary
artery smooth muscle cells.
J Mol Cell Cardiol.
2000;
32
2195-2206
-
10
Böning A, Herrmann G, Fraubd S. et al .
Chirurgische und interventionelle Koronarrevaskularisation
bei Diabetikern.
Dt Ärzteblatt.
2001;
98
919-923
-
11
Brooks M M, Jones R H, Bach R G. et al .
Predictors of mortality and mortality from
cardiac causes in the bypass angioplasty revascularization investigation
(BARI) randomized trial and registry. For the BARI Investigators.
Circulation.
2000;
101
2682-2689
-
12
Brooks R C, Detre K M.
Clinical trials
of revascularization therapy in diabetics.
Curr Opin Cardiol.
2000;
15
287-292
-
13
Carrozza J P, Kuntz R E, Fishman R F, Baim D S.
Restenosis after
arterial injury caused by coronary stenting in patients with diabetes mellitus.
Ann
Intern Med.
1993;
118
344-349
-
14
Elezi S, Kastrati A, Pache J. et al .
Diabetes
mellitus and the clinical and angiographic outcome after coronary
stent placement.
J Am Coll Cardiol.
1998;
32
1866-1873
-
15
Fox R.
American
Heart Association 2001 scientific sessions: late-breaking science-drug-eluting
stents.
Circulation.
2001;
104
E9052
-
16
Haffner S M.
Coronary
heart disease in patients with diabetes.
N Engl J Med.
2000;
342
1040-1042
-
17
Haffner S M, Lehto S, Ronnemaa T, Pyorala K, Laakso M.
Mortality from
coronary heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction.
N
Engl J Med.
1998;
339
229-234
-
18
Hammoud T, Tanguay J F, Bourassa M G.
Management
of coronary artery disease: therapeutic options in patients with
diabetes.
J Am Coll Cardiol.
2000;
36
355-365
-
19
Hasdai D, Rizza R A, Grill D E, Scott C G, Garratt K N, Holmes D R.
Glycemic
control and outcome of diabetic patients after successful percutaneous
coronary revascularization.
Am Heart J.
2001;
141
117-123
-
20
Heidland U E, Michel C J, Heintzen M P, Strauer B E.
Operation
oder Angioplastie bei Koronarer Herzerkrankung-eine Zusammenfassung
prospektiv randomisierter Studien.
Dtsch Med Wochenschr.
2000;
125
1475-1480
-
21
Herdeg C, Oberhoff M, Karsch K R.
Antiproliferative
stent coatings: Taxol and related compounds.
Semin Interv
Cardiol.
1998;
3
197-199
-
22
Jelesoff N E, Feinglos M, Granger C B, Califf R M.
Outcomes of
diabetic patients following acute myocardial infarction: a review
of the major thrombolytic trials.
Coron Artery Dis.
1996;
7
732-743
-
23
Kandzari D E, Kay J, O’Shea J C. et al .
Highlights from the American Heart Association
annual scientific sessions 2001: November 11 to 14, 2001.
Am
Heart J.
2002;
143
217-228
-
24
Kastrati A, Schomig A, Elezi S. et al .
Predictive factors of restenosis after
coronary stent placement.
J Am Coll Cardiol.
1997;
30
1428-1436
-
25
Kip K E, Faxon D P, Detre K M, Yeh W, Kelsey S F, Currier J W.
Coronary angioplasty
in diabetic patients. The National Heart, Lung, and Blood Institute
Percutaneous Transluminal Coronary Angioplasty Registry.
Circulation.
1996;
94
1818-1825
-
26
Kollros P R, Konkle B A.
Microvascular
disease in diabetes mellitus.
Coron Artery Dis.
1996;
7
702-707
-
27
Kornowski R, Mintz G S, Kent K M. et al .
Increased restenosis in diabetes mellitus
after coronary interventions is due to exaggerated intimal hyperplasia.
A serial intravascular ultrasound study.
Circulation.
1997;
95
1366-1369
-
28
Lele M, Sajid M, Wajih N, Stouffer G A.
Eptifibatide
and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated
binding of smooth muscle cells to thrombospondin and prothrombin.
Circulation.
2001;
104
582-587
-
29
Mehran R, Dangas G, Abizaid A. et al .
Treatment
of focal in-stent restenosis with balloon angioplasty alone versus
stenting: Short- and long-term results.
Am Heart J.
2001;
141
610-614
-
30
Miettinen H, Salomaa V.
Diabetes and macrovascular
disease.
Coron Artery Dis.
1996;
7
708-714
-
31
Moscucci M, Kline-Rogers E, Share D. et al .
Simple bedside additive tool for prediction
of in-hospital mortality after percutaneous coronary interventions.
Circulation.
2001;
104
263-268
-
32
Moustapha A, Assali A R, Sdringola S. et al .
Percutaneous and surgical interventions
for in-stent restenosis: long-term outcomes and effect of diabetes
mellitus.
J Am Coll Cardiol.
2001;
37
1877-1882
-
33
Roffi M, Chew D P, Mukherjee D. et al .
Platelet
glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic
patients with non-ST-segment-elevation acute coronary syndromes.
Circulation.
2001;
104
2767-2771
-
34
Sousa J E, Costa M A, Abizaid A C. et al .
Sustained suppression of neointimal proliferation
by sirolimus-eluting stents: one-year angiographic and intravascular
ultrasound follow-up.
Circulation.
2001;
104
2007-2011
-
35
Takagi T, Akasaka T, Yamamuro A. et al .
Troglitazone
reduces neointimal tissue proliferation after coronary stent implantation
in patients with non-insulin dependent diabetes mellitus: a serial
intravascular ultrasound study.
J Am Coll Cardiol.
2000;
36
1529-1535
-
36
vom Dahl J, Dietz U, Haager P K. et al .
Rotational atherectomy does not reduce
recurrent in-stent restenosis: results of the angioplasty versus
rotational atherectomy for treatment of diffuse in-stent restenosis
trial (ARTIST).
Circulation.
2002;
105
583-588
Korrespondenz
Prof. Dr. med. Jürgen vom
Dahl
Medizinische Klinik II
Kliniken Maria Hilf
GmbH
Krankenhaus St. Franziskus
Viersener Straße 450
41063 Mönchengladbach
Telefon: +49/2161/8922231
Fax: +49/2161/8922232
eMail: vomdahlj@mariahilf.de
